Cabaletta Bio (CABA) Stock Forecast & Price Target

Compare

1,103 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CABA Analyst Ratings

Strong Buy

9 Buy

2 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Cabaletta

Bio

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CABA Stock 12 Month Forecast

Average Price Target

$14.11

▲(798.73%Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Cabaletta Bio in the last 3 months. The average price target is $14.11 with a high forecast of $25.00 and a low forecast of $3.00. The average price target represents a 798.73% change from the last price of $1.57.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","26":"$26","6.5":"$6.5","19.5":"$19.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.5,13,19.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.06,3.8246153846153845,5.5892307692307694,7.353846153846154,9.118461538461538,10.883076923076924,12.647692307692308,14.412307692307694,16.176923076923078,17.94153846153846,19.706153846153846,21.470769230769232,23.235384615384614,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.06,2.986923076923077,3.913846153846154,4.840769230769231,5.7676923076923075,6.694615384615384,7.621538461538462,8.548461538461538,9.475384615384614,10.402307692307692,11.329230769230769,12.256153846153845,13.183076923076923,{"y":14.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.06,2.1323076923076925,2.204615384615385,2.276923076923077,2.3492307692307692,2.4215384615384616,2.493846153846154,2.5661538461538465,2.6384615384615384,2.710769230769231,2.7830769230769232,2.855384615384615,2.9276923076923076,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.41,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.19,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.88,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.64,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$14.11

Lowest Price Target$3.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$6→$4

Hold

154.78%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (NASDAQ: LQDA), ARS Pharmaceuticals (NASDAQ: SPRY) and Cabaletta Bio (NASDAQ: CABA)

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$15

Buy

855.41%

Upside

Reiterated

06/13/25

Cantor Fitzgerald Keeps Their Buy Rating on Cabaletta Bio (CABA)

Derek ArchilaWells Fargo

Wells Fargo

Hold

91.08%

Upside

Reiterated

06/11/25

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), Cabaletta Bio (NASDAQ: CABA) and Medtronic (NYSE: MDT)

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$25

Buy

1492.36%

Upside

Reiterated

06/11/25

Promising Efficacy and Strategic Advancements: Douglas Tsao's Buy Rating on Cabaletta Bio

Phil NadeauTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/11/25

Analysts' Top Healthcare Picks: Liquidia Technologies (LQDA), Cabaletta Bio (CABA)

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

06/11/25

Promising Clinical Data from Cabaletta Bio's RESET Trial Supports Buy Rating

Michael UlzMorgan Stanley

Morgan Stanley

$22

Buy

1301.27%

Upside

Reiterated

06/11/25

Promising Clinical Data and Positive Trajectory Support Buy Rating for Cabaletta Bio

Samantha SemenkowCiti

Citi

$13

Buy

728.03%

Upside

Reiterated

06/11/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Cabaletta Bio (NASDAQ: CABA), Cogent Biosciences (NASDAQ: COGT) and Biogen (NASDAQ: BIIB)

Yatin SunejaGuggenheim

Guggenheim

$23→$25

Buy

1492.36%

Upside

Reiterated

05/15/25

Cabaletta Bio price target raised to $25 from $23 at GuggenheimCabaletta Bio price target raised to $25 from $23 at Guggenheim

Trung HuynhUBS

UBS

$10→$7

Buy

345.86%

Upside

Reiterated

04/01/25

Cabaletta Bio price target lowered to $7 from $10 at UBSCabaletta Bio price target lowered to $7 from $10 at UBS

Benjamin BurnettStifel Nicolaus

Stifel Nicolaus

$26→$13

Buy

728.03%

Upside

Reiterated

03/31/25

Analysts' Top Healthcare Picks: Olema Pharmaceuticals (OLMA), Connect Biopharma Holdings (CNTB)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gavin Clark-GartnerEvercore ISI

Evercore ISI

$6→$4

Hold

154.78%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (NASDAQ: LQDA), ARS Pharmaceuticals (NASDAQ: SPRY) and Cabaletta Bio (NASDAQ: CABA)

Joshua SchimmerCantor Fitzgerald

Cantor Fitzgerald

$15

Buy

855.41%

Upside

Reiterated

06/13/25

Cantor Fitzgerald Keeps Their Buy Rating on Cabaletta Bio (CABA)

Derek ArchilaWells Fargo

Wells Fargo

Hold

91.08%

Upside

Reiterated

06/11/25

Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB), Cabaletta Bio (NASDAQ: CABA) and Medtronic (NYSE: MDT)

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$25

Buy

1492.36%

Upside

Reiterated

06/11/25

Promising Efficacy and Strategic Advancements: Douglas Tsao's Buy Rating on Cabaletta Bio

Phil NadeauTD Cowen

TD Cowen

―

Buy

―

Reiterated

06/11/25

Analysts' Top Healthcare Picks: Liquidia Technologies (LQDA), Cabaletta Bio (CABA)

Sami CorwinWilliam Blair

William Blair

―

Buy

―

Reiterated

06/11/25

Promising Clinical Data from Cabaletta Bio's RESET Trial Supports Buy Rating

Michael UlzMorgan Stanley

Morgan Stanley

$22

Buy

1301.27%

Upside

Reiterated

06/11/25

Promising Clinical Data and Positive Trajectory Support Buy Rating for Cabaletta Bio

Samantha SemenkowCiti

Citi

$13

Buy

728.03%

Upside

Reiterated

06/11/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Cabaletta Bio (NASDAQ: CABA), Cogent Biosciences (NASDAQ: COGT) and Biogen (NASDAQ: BIIB)

Yatin SunejaGuggenheim

Guggenheim

$23→$25

Buy

1492.36%

Upside

Reiterated

05/15/25

Cabaletta Bio price target raised to $25 from $23 at GuggenheimCabaletta Bio price target raised to $25 from $23 at Guggenheim

Trung HuynhUBS

UBS

$10→$7

Buy

345.86%

Upside

Reiterated

04/01/25

Cabaletta Bio price target lowered to $7 from $10 at UBSCabaletta Bio price target lowered to $7 from $10 at UBS

Benjamin BurnettStifel Nicolaus

Stifel Nicolaus

$26→$13

Buy

728.03%

Upside

Reiterated

03/31/25

Analysts' Top Healthcare Picks: Olema Pharmaceuticals (OLMA), Connect Biopharma Holdings (CNTB)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cabaletta Bio

1 Month

xxx

Success Rate

6/11 ratings generated profit

Average Return

-0.04%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of -0.04% per trade.

3 Months

xxx

Success Rate

14/24 ratings generated profit

Average Return

+73.38%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +73.38% per trade.

1 Year

Douglas TsaoH.C. Wainwright

Success Rate

12/24 ratings generated profit

Average Return

+154.18%

reiterated a buy rating 18 days ago

Copying Douglas Tsao's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +154.18% per trade.

2 Years

xxx

Success Rate

8/24 ratings generated profit

Average Return

+63.73%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of +63.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CABA Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CABA has received 16 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. CABA average Analyst price target in the past 3 months is 14.11.

Each month's total comprises the sum of three months' worth of ratings.

CABA Financial Forecast

CABA Earnings Forecast

Next quarter’s earnings estimate for CABA is -$0.65 with a range of -$0.76 to -$0.11. The previous quarter’s EPS was ―. CABA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year CABA has Preformed in-line its overall industry.

No data currently available

CABA Sales Forecast

Next quarter’s sales forecast for CABA is $4.17M with a range of $0.00 to $25.00M. The previous quarter’s sales results were ―. CABA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 70.18% of the time in the same period. In the last calendar year CABA has Preformed in-line its overall industry.

CABA Stock Forecast FAQ

What is CABA’s average 12-month price target, according to analysts?

Based on analyst ratings, Cabaletta Bio’s 12-month average price target is 14.11.

What is CABA’s upside potential, based on the analysts’ average price target?

Cabaletta Bio has 798.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CABA a Buy, Sell or Hold?

Cabaletta Bio has a consensus rating of Strong Buy which is based on 9 buy ratings, 2 hold ratings and 0 sell ratings.

What is Cabaletta Bio’s price target?

The average price target for Cabaletta Bio is 14.11. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $3.00. The average price target represents 798.73% Increase from the current price of $1.57.

What do analysts say about Cabaletta Bio?

Cabaletta Bio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of CABA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Cabaletta Bio (CABA) Stock Forecast & Price Target

CABA Analyst Ratings

CABA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cabaletta Bio

CABA Analyst Recommendation Trends

CABA Financial Forecast

CABA Earnings Forecast

CABA Sales Forecast

CABA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts